Teva’s Phase 2B Migraine Program
Teva Pharmaceutical Industries Ltd., has announced that Lancet Neurology published online, as back-to-back articles, the results from two Phase 2b…
Pharmaceuticals, Biotechnology and Life Sciences
Teva Pharmaceutical Industries Ltd., has announced that Lancet Neurology published online, as back-to-back articles, the results from two Phase 2b…
Novartis announced on Wednesday that results from the pivotal Phase III FUTURE 1 study for Secukinumab in psoriatic arthritis (PsA)…
Sanofi announced on Tuesday that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for lixisenatide.
ImmuPharma PLC the specialist drug discovery and development company, has announced the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.
Veidekke’s Danish subsidiary Hoffmann has been awarded a contract to build a new national research and treatment centre for particle therapy in Aarhus in Jutland.
Several individuals in German-speaking Switzerland are suspected of offences against the Therapeutic Products Act.
Pfizer Inc., the specialist in making contraceptive medicine, best known for making Viagra, has announced that its injectable contraceptive, Sayana Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection.
New clinical data and abstracts on Roche’s Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF) are being presented at the European Respiratory Society (ERS) congress in Amsterdam.
Bayer CropScience inaugurated its new European Oilseed Processing Center in Monheim at a ceremony attended by industry representatives, authorities, agricultural stakeholders and customers.
Allergan plc has updated its second-half 2015 continuing operations financial forecast. The forecast reflects adjustments for the upcoming expected discontinued operations